The latest price target for GRI Bio (NASDAQ:GRI) was reported by Ascendiant Capital on October 8, 2024. The analyst firm set a price target for $12.00 expecting GRI to rise to within 12 months (a possible 1566.67% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for GRI Bio (NASDAQ:GRI) was provided by Ascendiant Capital, and GRI Bio initiated their buy rating.

There is no last upgrade for GRI Bio

There is no last downgrade for GRI Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GRI Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GRI Bio was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.

While ratings are subjective and will change, the latest GRI Bio (GRI) rating was a initiated with a price target of $0.00 to $12.00. The current price GRI Bio (GRI) is trading at is $0.72, which is within the analyst’s predicted range.